Author

admin

Browsing

The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After peaking at $341 in July, the stock plunged by over 25% to the current $260. So, is Amgen a good healthcare stock to buy in 2025?

Amgen stock plunged after weight loss disappointments

The main reason why the Amgen share price crashed is that MariTide, its experimental weight loss drug failed to outperform those of Eli Lilly and Novo Nordisk. Data released in October showed that the drug helped patients lose 20% of their weight in the first year. The number needed to be at least 25% for it to compete with its top rivals. 

The weight loss industry has become one of the most profitable and popular sectors in healthcare. It will help Eli Lilly become a $1 trillion company in 2025. 

Its performance has pushed more companies to innovate and develop better drugs to compete with those of Novo and Lilly. 

However, a company like Amgen will do well even without a presence in the weight loss industry. Besides, there are signs that the sector is starting to slow as evidenced by the Novo Nordisk stock, which has crashed by over 40% from its highest level in 2024. 

Also, Amgen’s weight loss drug had little chance to gain market share because of Lilly’s and Novo’s dominance. Data shows that Lilly’s Zepbound has about 40% share in the US. Combined, the two firms control about 68% of the market, and it will be very difficult for other drugs to gain market share. 

Amgen business is doing well but faces risks

Amgen is in a difficult situation. While its business is doing well, it faces substantial risks related to its patent expiry. It needed its weight-loss drug to replenish its patent-expiry drugs. 

The most recent financial results showed that Amgen’s revenues rose by 23% in the third quarter, with ten drugs having at least double-digit sales. The success was mainly due to drugs like Tezspire, Blincyto, Evenity, and Tavneos. 

The company’s sales growth was mainly due to its $28 billion acquisition of Horizon Therapeutics. Excluding this buyout, Amgen would have had about 8% revenue growth, which was an equally good one. 

Repatha and Evenity sales jumped by 40% and 30% during the quarter, while Blincyto jumped by 49%. Tezspire’s revenue rose by 67%, while Tavneos sales doubled because of higher volume.

Analysts expect Amgen to continue developing its weight loss drug or even make a major acquisition this year. Many smaller companies are developing similar products, and some of the most potential companies to buy include Viking Therapeutics and Structure Therapeutics.

Wall Street analysts are upbeat about the Amgen stock price and its business despite the many challenges. The expectation is that its revenue for 2024 will be $33 billion, followed by $34.36 billion in the next financial year. 

The Amgen stock price forecast is $322, higher than the current $260, pointing to more gains ahead.

Amgen stock price analysis

AMGN chart by TradingView

The daily chart shows that the AMGN share price peaked at $341 in 2024 and then plunged to $255 last year. It has formed a death cross chart pattern as the 50-day and 200-day Exponential Moving Averages (EMA) crossed each other. This is one of the most bearish patterns in the market. 

The stock has also moved below the 50% retracement point. On the other hand, it has found support at $255, which coincides with the 61.8% retracement and the lowest swing in April 2024. It also fell below the key support at $276, its highest level in 2022. 

There are signs that the stock has formed a falling wedge chart pattern, a popular bullish reversal sign. Therefore, a contrarian case can be made of the stock. If this happens, the next point to watch will be at $276, which is about 6% above the current level. It could also rebound to the psychological point at $300.

The post Amgen stock price formed a death cross: will it rebound in 2025? appeared first on Invezz

American Express continued its strong rally in 2024, becoming one of the best-performing companies in the S&P 500 index. AXP stock soared to a record high of $307, up by over 57%. Since its lowest level in 2020, it has surged more than 370%, bringing its market cap to over $209 billion. 

American Express stock jumped as growth continued

American Express, one of the top investments by Warren Buffett, had a strong performance in 2024. 

It has mostly benefited from the relatively high interest rates and the rising demand for its credit cards, especially among young people. 

AXP’s net interest income rose from over $8.6 billion in 2019 to over $15 billion in the trailing twelve months. This growth has helped to push its annual revenue from $39 billion to $59 billion in the same period. 

The most recent results showed that American Express’s business continued well in the third quarter. 

Its total billed business rose by 6% to $387 billion, bringing the nine-month billings to over $1.14 trillion. 

This growth translated to a 8% revenue growth of $16.6 billion and its net income to $2.5 billion. As a result, the management boosted its conservative forward guidance, as the number of cardholders rose. It expects its earnings per share to be between $13.75 and $14.05.

American Express business will likely continue to do well in the next few years, as it will take advantage of higher interest rates. Its annual revenue is expected to be about $66 billion, representing a near 10% increase from a year earlier. 

The company’s revenue is expected to grow to $71 billion this year. If this trend continues, it will likely have over $100 billion in annual revenue by 2030. The management believes that the company will deliver double-digit returns in the next few years.

Read more: American Express stock has upside, but a pullback can’t be ruled out

Its most important catalyst is that the younger generation is joining its business. Data shows that about three-quarters of its accounts opened in 2023 came from millennials and Gen Z. 

Most importantly, many of these customers are going straight to its $695 annual fee consumer platinum card. In the past, many consumers used to start with the zero-fee card and worked their way up.

Another important factor is that American Express is fairly immune to the ongoing credit card default rates in the US. That’s because Amex mostly focuses on affluent clients unlike other credit card companies. 

The most recent results showed that credit cards with 30+ days due stood at just 1.3%, lower than the pre-pandemic level of 1.5%. Also, the net write-off rates has dropped from the pre-pandemic level of 2.2% to 1.9%. 

Still, a key concern for American Express is that it is a fairly overvalued company. One way to assess this is to compare its valuation with its annual profits. With a market cap of over $202 billion and annual profits of almost $10 billion, American Express has a PE of about 20. 

AXP stock price analysis

AXP stock chart | Source: TradingView

The weekly chart shows that the American Express stock price has been in a strong uptrend in the past few years. It has found some substantial resistance at the $300 level. The stock has remained above the 50-week and 100-week moving averages, pointing to a potential mean reversion. 

There are signs that the Relative Strength Index (RSI) and the MACD indicators have formed a bearish divergence pattern. Therefore, the stock will likely pull back some more this year and then resume its uptrend. As we wrote in this Dow Jones report, there is a likelihood that some of the top gainers in 2024 will reverse this year. That would see it drop to $250 and then rebound.

The post Is American Express a good Warren Buffett stock for 2025? appeared first on Invezz

American Express continued its strong rally in 2024, becoming one of the best-performing companies in the S&P 500 index. AXP stock soared to a record high of $307, up by over 57%. Since its lowest level in 2020, it has surged more than 370%, bringing its market cap to over $209 billion. 

American Express stock jumped as growth continued

American Express, one of the top investments by Warren Buffett, had a strong performance in 2024. 

It has mostly benefited from the relatively high interest rates and the rising demand for its credit cards, especially among young people. 

AXP’s net interest income rose from over $8.6 billion in 2019 to over $15 billion in the trailing twelve months. This growth has helped to push its annual revenue from $39 billion to $59 billion in the same period. 

The most recent results showed that American Express’s business continued well in the third quarter. 

Its total billed business rose by 6% to $387 billion, bringing the nine-month billings to over $1.14 trillion. 

This growth translated to a 8% revenue growth of $16.6 billion and its net income to $2.5 billion. As a result, the management boosted its conservative forward guidance, as the number of cardholders rose. It expects its earnings per share to be between $13.75 and $14.05.

American Express business will likely continue to do well in the next few years, as it will take advantage of higher interest rates. Its annual revenue is expected to be about $66 billion, representing a near 10% increase from a year earlier. 

The company’s revenue is expected to grow to $71 billion this year. If this trend continues, it will likely have over $100 billion in annual revenue by 2030. The management believes that the company will deliver double-digit returns in the next few years.

Read more: American Express stock has upside, but a pullback can’t be ruled out

Its most important catalyst is that the younger generation is joining its business. Data shows that about three-quarters of its accounts opened in 2023 came from millennials and Gen Z. 

Most importantly, many of these customers are going straight to its $695 annual fee consumer platinum card. In the past, many consumers used to start with the zero-fee card and worked their way up.

Another important factor is that American Express is fairly immune to the ongoing credit card default rates in the US. That’s because Amex mostly focuses on affluent clients unlike other credit card companies. 

The most recent results showed that credit cards with 30+ days due stood at just 1.3%, lower than the pre-pandemic level of 1.5%. Also, the net write-off rates has dropped from the pre-pandemic level of 2.2% to 1.9%. 

Still, a key concern for American Express is that it is a fairly overvalued company. One way to assess this is to compare its valuation with its annual profits. With a market cap of over $202 billion and annual profits of almost $10 billion, American Express has a PE of about 20. 

AXP stock price analysis

AXP stock chart | Source: TradingView

The weekly chart shows that the American Express stock price has been in a strong uptrend in the past few years. It has found some substantial resistance at the $300 level. The stock has remained above the 50-week and 100-week moving averages, pointing to a potential mean reversion. 

There are signs that the Relative Strength Index (RSI) and the MACD indicators have formed a bearish divergence pattern. Therefore, the stock will likely pull back some more this year and then resume its uptrend. As we wrote in this Dow Jones report, there is a likelihood that some of the top gainers in 2024 will reverse this year. That would see it drop to $250 and then rebound.

The post Is American Express a good Warren Buffett stock for 2025? appeared first on Invezz

United Airlines stock had a great year, surging by over 140%, beating benchmark indices like the S&P 500 and Dow Jones. UAL also did better than popular technology companies like Microsoft, Amazon, and Alphabet.

United Airlines did much better than other airline groups like Delta, American Airlines, Southwest, and JetBlue. So, why did the UAL stock price surge in 2024, and will the rally gain steam this year?

Profitability growth continued

United Airlines stock price surged in 2024 mostly because of the ongoing recovery of the civil aviation industry, focus on profitability, and its capital returns to investors. 

The management has worked hard and continued to boost its profit margins in the past few years as it aims to move in par with Delta Air Lines, the gold standard in the industry.

Its revenue has continued growing in the past few years, and analysts expect the trend to continue. It generated over $15 billion in annual revenue in 2020 as the pandemic forced it to stop flying.

The revenue growth then continued in 2021, when it made $24 billion. Its trailing twelve-month (TTM) revenue stood at $60 billion. 

Analysts are upbeat about United Airlines’s business. The average revenue estimate for 2024 is $56.65 billion, up from $54 billion a year earlier. It will then cross the $60 billion in the next financial year. 

United Airlines’ profits are also growing. In the trailing twelve months, they went from a net loss of $1.6 billion in 2021 to a net profit of $2.7 billion. 

This growth has helped the company return funds to its shareholders. In the last quarter, it announced a $1.5 billion share repurchase program, a move that is expected to reduce its share count and boost its earnings per share.

The management hopes to continue growing its business, especially its international segment, which the management to double.

Read more: Here’s why United Airlines stock is beating American, IAG, Delta

Potential risks remain

Still, United Airlines stock face numerous risks ahead. The first one is that competition, especially on its international route, is expected to be stiff in the next few years as more airlines intensify their volume. This stiff competition may affect its volume and pricing.

Second, airlines tend to be highly cyclical businesses, which experience boom and bust cycles. The past few years have been boom periods, meaning that a bust may happen either in 2025 or later.

Third, the stock has become fairly overvalued after more than quadrupling in the past few years. As such, there is a risk that it will go through a valuation reset when it gets to the average analyst estimate of $110.

United Airlines stock has double topped

The other risk to the UAL share price is that it is seeing signs of double-topping at $104. A double top is one of the most popular bearish chart patterns in the market. In this case, the neckline is at $90.13.

The stock also remains above the 50-day and 100-day moving averages. That is a sign that it will have a mean reversion situation soon. A mean reversion is when a stock retreats and falls back to the average prices over time. In this case, a mean reversion to the 100 day moving average would see it drop to around $80.

On the flip side, more United Airlines stock surge will be confirmed if it rises and moves above the double-top level at $104.

The post United Airlines stock boomed in 2024: time to book profits? appeared first on Invezz

After a lacklustre performance in recent years, Indian large-cap stocks could see a comeback in 2025, driven by attractive valuations resulting from foreign investor selling and the potential for strong corporate earnings.

A CNBC-TV18 poll which gathered insights from 61 fund managers, high-net-worth individuals, and market dealers indicated a strong leaning in favour of large-cap stocks for 2025.

Further, according to the latest report by Canara Robeco Mutual Fund, the fall of the Nifty 100 index- which tracks the performance of India’s 100 largest companies by market capitalisation- to near all-time lows creates a significant opportunity for mean reversion, where valuations return to their historical norms.

Further, the report says, that the fact that these stocks represent leaders in their respective industries, they are more resilient and more capable of navigating global market volatility, as well as capitalising on long-term economic trends.

Why valuations are favouring large caps?

V K Vijayakumar, Chief Investment Strategist, Geojit Financial Services, recently said that FIIs sold equities worth Rs 1.19 lakh crore in 2024, even though they invested nearly Rs 1.21 lakh crore through primary markets, especially when the year saw a surfeit of initial share sales.

According to Bloomberg, global funds offloaded over $750 million worth of stocks in 2024, exacerbated by heavy selling in October and November.

One of the major reasons behind the heavy selling was the premium valuations of Indian stocks in the wake of slowing earnings growth.

Source: Moneycontrol

In September, the Nifty 50 index, which comprises the top 50 equity stocks, was trading at a price-to-earnings ratio of 24.7x, which was in line with its 5-year average, but higher than the 10-year average of 23.4x.

Currently, Nifty 50 is trading at a PE ratio of 21.9, whereas Nifty 100 is trading at a PE ratio of 22.4.

Nimesh Chandan, chief investment officer at Bajaj Finserv, which manages over $1.8 billion in assets, told CNBC,

Large caps have borne the brunt of selling by foreign investors, and valuations are attractive.

The Canara Robeco report added, “The domestic large-cap universe currently stands near its 3-year historical average while being undervalued against the Nifty 500 broader market index. This may open an opportunity for the large-cap space to be favourable for the upcoming period as per our belief.”

5 large-cap stocks that analysts are bullish on

Axis Bank share price target

Axis Bank is covered by 37 brokers, who have assigned an average rating of 4.33 out of 5.

The stock’s average target price is ₹1,349, suggesting a potential upside of 26% from its current price of ₹1,073.

Hindustan Unilever (HUL) share price target

Hindustan Unilever is tracked by 35 brokers, with an impressive average rating of 4.67.

Analysts have set an average target price of ₹2,934, indicating a 26% upside from the current price of ₹2,321.

IndusInd Bank share price target

IndusInd Bank has an average rating of 4.69 from 34 brokers.

The stock has an average target price of ₹1,630, reflecting a massive 67% upside from its current market price of ₹977.

Tata Motors share price target

Tata Motors has earned an average rating of 4.14 from 31 brokers.

Analysts project an average target price of ₹1,052, highlighting a potential upside of nearly 40% from the current price of ₹749.

State Bank of India (SBI) share price target

SBI is covered by 30 brokers, with an average rating of 4.75.

The average target price for the stock is ₹1,010, offering a potential upside of 27% from its current market price of ₹793.

The post Tata Motors, SBI, and 3 more large-cap stocks analysts are bullish on for 2025 appeared first on Invezz

Indonesia’s delay in implementing its B40 biodiesel mandate is creating ripples through the global palm oil market, raising questions about export volumes, domestic consumption, industry stability, and future pricing trends.

The initiative aimed to raise palm oil blending in biodiesel to 40% from the current 35%, but regulatory bottlenecks have stalled progress, leaving traders and producers in limbo.

As the world’s largest palm oil producer, Indonesia’s biodiesel policies significantly influence global markets, making the delay a pivotal development for traders.

What is Indonesia’s B-40 mandate?

Initially planned for rollout on 1 January 2024, the B40 mandate has yet to take effect due to the absence of technical regulations and official decrees.

The policy was expected to curb Indonesian palm oil exports by redirecting supply to domestic biodiesel production.

The delay has left biodiesel producers, such as members of APROBI, unable to finalise contracts, and state energy firm Pertamina awaiting clear directives to operationalise its refineries for B40 production.

For global palm oil traders, this uncertainty is significant.

The mere announcement of the B40 policy had already driven Malaysia’s benchmark palm oil prices nearly 20% higher earlier in 2024, as markets anticipated reduced exports from Indonesia.

The current impasse has now tempered those expectations, leaving traders to reassess the potential impact on supply chains, pricing, and overall market dynamics.

Indonesia palm oil exports

Indonesia’s annual allocation of 15.62 million kilolitres (4.13 billion gallons) of palm oil-based biodiesel for 2025 is critical to understanding the policy’s impact.

However, with implementation delayed, traders are struggling to estimate how much palm oil will remain available for export.

This uncertainty could disrupt market dynamics, particularly in neighbouring Malaysia, which competes for global palm oil demand, and potentially shift the balance of trade in the region.

Moreover, concerns about the scope of government subsidies for B40 have added to the confusion.

Analysts note that Indonesia may only subsidise biodiesel for non-industrial use, which accounts for less than half of the country’s demand.

If this materialises, the policy could fall short of its intended impact, undermining both domestic consumption targets and global market expectations.

This raises broader concerns about policy consistency in Indonesia’s biofuel strategy.

Palm oil price outlook

The delayed implementation of the B40 policy presents a mixed outlook for palm oil markets.

On the one hand, the uncertainty may cap bullish sentiment, as traders remain cautious about Indonesia’s ability to execute the mandate effectively.

On the other, any sudden progress in rolling out the policy could lead to rapid price adjustments, particularly if export volumes are curtailed, potentially reshaping global supply chains.

For Indonesia, resolving the bottlenecks is essential not just for domestic energy goals but also for maintaining its leadership in the global palm oil market.

Until then, traders and producers alike must navigate a landscape of shifting expectations, regulatory ambiguity, and uncertain timelines for a policy that could significantly impact the sector.

The post What Indonesia’s B40 biodiesel delay means for palm oil traders appeared first on Invezz

The year 2024 witnessed a surge in the valuation of Artificial Intelligence (AI) stocks, fueled by a confluence of factors.

Rapid advancements in AI technology, coupled with growing investor enthusiasm and a recognition of the transformative potential of AI across various sectors, propelled many AI-focused companies to significant stock price appreciation

AI continued to dominate corporate discourse in 2024, with over 40% of S&P 500 companies mentioning it on their Q2 earnings calls.

This trend, following a dramatic surge in 2023, underscores the growing significance of AI across various sectors.

The greatest example of this AI-led surge in 2024 was Applovin.

AppLovin started the year with a market cap of around $13 billion, known for its investments in mobile gaming studios behind titles like “Woody Block Puzzle” and “Bingo Story.”

By year-end, its valuation surged to over $110 billion, surpassing companies like Starbucks, Intel, and Airbnb, with shares up 758% this year, leading all tech companies.

Will AI stocks continue to surge in 2025?

Analysts at global research firm UBS say that while there are both negative and positive drivers for AI stocks in the coming year, they should be able to perform well.

In its latest research note on AI, the brokerage argued that contrary to the widespread belief that AI stocks’ valuations are stretched, the rally in AI-related stocks over the last two years has primarily been driven by solid earnings growth, not an expansion in price-to-earnings (P/E) multiples.

For instance, NVIDIA’s forward P/E was around 40x when ChatGPT was launched in late November 2022. Despite the stock’s remarkable rise, its P/E multiple has decreased to the low 30s, the brokerage highlighted.

Looking forward, UBS expects the AI theme to continue its strong earnings growth without needing a P/E rerating. The analysts forecast that their AI portfolio will deliver 25% EPS growth in 2025, following 35% EPS growth in 2024.

Even with a moderate derating of P/E multiples, UBS estimates mid-teen returns in 2025, which would still be impressive after two years of strong performance.

However, UBS highlights factors that could influence the P/E multiple. On the negative side, slower-than-expected AI monetization and macroeconomic or product cycle uncertainties could pressure P/E multiples.

On the positive side, faster monetisation and stronger cash returns could support a rerating.

Volatility in AI stocks in 2025

UBS acknowledges that the easy gains in AI stocks are behind us, and investors should prepare for slightly more volatile returns in 2025.

This expectation stems from the more mature stage of the AI rally, with uncertainties surrounding product cycles and tariff-related issues potentially leading to short-term profit-taking by tactical investors.

This could result in greater volatility, as per the analysts.

Investors can take advantage of heightened volatility through structured strategies, particularly by buying dips in quality AI stocks, as the focus is expected to shift back to strong fundamentals.

UBS also highlights that regulatory debates could add to volatility in AI stocks.

However, based on lessons from the internet and smart device eras, they believe that regulation-driven corrections tend to be short-lived, with long-term performance driven by fundamentals.

AI regulations to take shape in 2025

In 2024, AI regulations started to catch up, and UBS expects more rules to be introduced in 2025.

While regulations have always posed a risk to the tech sector, this is particularly true for AI, given the rapid evolution of the industry.

UBS anticipates that AI regulations will accelerate in the coming years, with increased regulatory attention expected from the new US administration, as well as in China and Europe.

The firm sees early-stage regulations as beneficial, as they can guide more orderly growth for the sector.

However, the introduction of regulations during the later stages of development can cause significant damage, as seen in other industries like education and fintech.

UBS stresses that while AI regulations, including export controls, are an important risk to monitor, any significant correction driven by geopolitics or regulations could present a buying opportunity for long-term investors.

The post Will Nvidia, and other AI stocks continue dream run in 2025? Analysts weigh in appeared first on Invezz

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024.

It’s what helped Novo Nordisk A/S (CPH: NOVO-B) become the Europe’s largest company by market cap and made many forecast Eli Lilly & Co (NYSE: LLY) to emerge as the world’s first healthcare firm to hit $1.0 trillion valuation.

Still, analysts at UBS expect a more uncertain macroeconomic backdrop to make it difficult for the biopharma space to outperform in 2025.

RFK spells uncertainty for weight-loss drugs

UBS is somewhat dovish on the biopharmaceutical sector for the short to medium term primarily because Donald Trump has named Robert F. Kennedy Jr. to lead the Department of Health and Human Services.

RFK is a known vaccine skeptic who “has publicly criticised proposals to allow government health plans to pay for GLP-1 (weight-loss) drugs due to financial concerns.”

So, it’s uncertain how his appointment as the head of HHS will affect the weight-loss drugs industry, the investment firm told clients in its report on Tuesday.

Note that the anti-obesity drugs market has grown more than three-fold over the past four years to well over $6.0 billion in 2024.

UBS still forecasts growth in GLP-1

Despite macroeconomic uncertainty, however, UBS continues to see growth in GLP-1 and expects that theme to continue to dominate in 2025.

Its analysts recommend sticking to space leaders, Eli Lilly and Novo Nordisk, to play the potential upside in the weight-loss drugs market that’s broadly expected be worth $100 billion by 2030.

“Given the addressable market size, the range of potential outcomes is wide with potential for the Eli Lilly and Novo Nordisk franchises to grow beyond 2031 with successful pipeline read-outs.”

Zepbound sales totalled more than $1.2 billion in Lilly’s latest reported quarter. The blockbuster weight-loss treatment along with Mounjaro contributed some 42% to the company’s overall revenue in Q3.

Wegovy, on the other hand, brought in $2.5 billion for Novo Nordisk in the third quarter that translates to an incredible 79% growth on a year-over-year basis.

How high could Lilly and Novo stock go?

UBS favours sticking to Eli Lilly and Novo Nordisk to play anti-obesity drugs because a potentially more uncertain macroeconomic backdrop could weigh on competition as well.  

“While we acknowledge there’s potential competition entering, we see limited penetration given the entrenchment of Lilly and Novo,” its analysts argued in a research note today.

They also expect Zepbound and Wegovy sales to increase as supply improves further in 2025. Plus, both Eli Lilly and Novo Nordisk are committed to an oral version of their weight-loss treatment as well.

UBS currently has a $1,100 price target on Eli Lilly stock that translates to a more than 40% upside from current levels and DKK 1,100 price target on Novo Nordisk that suggests an even bigger 75% upside.

The post Weight-loss drug investments: why 2025 could be a game-changer appeared first on Invezz

Famed investor Jim Cramer expects two outperformers: Wells Fargo and TJX Companies to have a strong 2025.

Both stocks are on track to closing this year with a well over 30% gain. Still, the Mad Money host is convinced that neither of them are out of juice just yet.

Here’s why Cramer expects WFC and TJX to have another stellar year.

Wells Fargo & Co (NYSE: WFC)

Jim Cramer expects next year to be a “much better” one for Wells Fargo as the regulatory environment is broadly expected to turn more lenient under Donald Trump as the President of the United States.

He’s bullish because the new government may even choose to remove the $1.95 trillion asset cap that has weighed on WFC for years.

“The idea that this foolishness by regulators can continue in 2025 is pretty unfathomable. While Wells Fargo has done a lot despite a cap on its activities, it’s inconceivable that lifting the restriction won’t matter to the stock,” he told members of his Investing Club today.

A more accommodative regulatory stance under the Trump administration could lead to increased mergers and acquisitions as well, which could serve as another meaningful tailwind for WFC.

Additionally, Wells Fargo could benefit as the US Federal Reserve continues to lower interest rates, thereby stimulating borrowing, according to Jim Cramer.

Wells Fargo stock currently pays a healthy dividend yield of 2.27% that makes up for another good reason to have it in your portfolio. Wall Street currently has a consensus “overweight” rating on WFC shares.

TJX Companies Inc (NYSE: TJX)

Jim Cramer expects TJX to see a strong 2025 because it could emerge as a beneficiary of the potential increase in tariffs as Donald Trump takes office in January.

Trump’s trade tariffs could lead to higher prices at traditional retailers, making consumers shift to off-price names like TJ Maxx for affordability. This could result in a solid footfall and higher sales for Framingham headquartered chain of discount department stores, he argued.

The Mad Money host also cited operational acumen and expertise in inventory management as reasons why TJX stock price could rally further in 2025.

TJX Companies increased its stake in two off-price retailers, one in Mexico and another in the Middle East this year. That could help unlock further upside in its share price as well.

The New York listed firm handily topped Street estimates in its latest reported quarter, signalling its “values and treasure hunt shopping experience are appealing to a wide range of customers.”

Much like WFC, shares of this off-price retailer also pay a dividend yield of 1.24% at writing that makes them all the more attractive for income investors. Wall Street currently sees a 10% upside in TJX stock to $134 on average.

The post Jim Cramer highlights two stocks set to continue outperforming in 2025 appeared first on Invezz

A fake cryptocurrency led to millions in losses for several Vietnamese residents who were hoping to spawn life-changing gains from their investments.

Recently, law enforcement in the Vietnamese city of Hanoi apprehended several suspects who had ties to a local company that had branded itself as “Million Smiles.”

The dubious firm has allegedly stolen over 30 billion Vietnamese dong, roughly 300 million locals and 100 businesses.

A cryptocurrency backed by ancient treasures

According to local media outlet VTV, Million Smiles reportedly posed as a humanitarian corporation that was working for the benefit of society.

They sold dreams of riches out of small investments by promising life-changing returns and financial freedom through their so-called Quantum Financial System (QFS) coin.

To the victims of the elaborate scam, QFS was no ordinary cryptocurrency.

It was an asset supposedly backed by ancient treasures and heritage assets, passed down for generations and preserved by prominent family dynasties.

Those willing to bet on the future success of these ancient assets would acquire QFS coin from Million Smiles, who lured in unsuspecting victims, claiming that early movers would be able to generate billions when the value of the token skyrockets in the future.

To further incentivise their patrons, Million Smiles promised QFS owners access to the QFS financial ecosystem, where both individuals and businesses could acquire loans without having to pay interest or offer any sort of collateral. 

With this pitch, the fraudulent firm solicited investments ranging from 4-5 million VND (approximately $190) per coin for individuals and 39 million VND (around $1,350) per coin from businesses.

By the time law enforcement dismantled the operation, the scammers had made roughly 30 billion VND ($1.25 million) from its victims, some of whom were low-income individuals.

Among them was a forestry worker from Yên Bái who invested 39 million VND ($1,350) only to have been left with a valueless cryptocurrency backed by nothing.

A portion of the proceeds from the crime was used to acquire luxurious office spaces in upscale villa areas to add more legitimacy to the entire act.

Masterminds apprehended

Per the VTV report, the police are investigating the General Director of “Million Smiles,” along with seven other individuals connected to the fraudulent QFS cryptocurrency scheme.

A raid has been conducted at the company’s headquarters, and authorities have seized documents, computers, and other evidence, uncovering the extent of the operation and its fraudulent activities.

Further, authorities managed to thwart an upcoming promotional meeting scheduled to host 300 potential investors at Thiên Đường Bảo Sơn in Hanoi. The event was intended to market the fraudulent QFS coin further.

The police have also issued a notice urging victims of the scam to come forward and report their cases to ensure their rights and interests are protected under the law.

With cryptocurrencies dominating headlines, thanks to their growing role in global politics and Bitcoin’s historic rise beyond $100K, scammers have seized the moment, weaving elaborate schemes to exploit the hype.

As previously reported by Invezz, investment frauds accounted for approximately 71% of the $5.6 billion stolen from the crypto industry last year. 

The post How a $1 million crypto scam baited Vietnamese investors with ancient treasures appeared first on Invezz